Although novel therapies improve the survival of CLL patients, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the B-cell lymphoma 2 (Bcl2) inhibitor venetoclax, high-risk CLL remains incurable (2–5). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.